The aim of this study was the development of an alternative testing method based on human embryonic stem cells for prenatal developmental toxicity with particular emphasis on early neural development. To this purpose, we designed an in vitro protocol based on the generation of neural rosettes, representing the in vitro counterpart of the developing neural plate and neural tube, and we challenged this complex cell model with retinoic acid (RA), a wellknown teratogenic agent. The cells were exposed to different concentrations of RA during the process of rosettes formation. Morphological and molecular parameters were evaluated in treated as compared with untreated cells to detect both cytotoxicity and specific neural toxicity. Transcriptomic analysis was performed with microarray Affymetrix platform and validated by quantitative realtime PCR for genes relevant to early neural development such as HoxA1, HoxA3, HoxB1, HoxB4, FoxA2, FoxC1, Otx2, and Pax7. The results obtained demonstrated that neural rosette forming cells respond to RA with clear concentration-dependent morphological, and gene expression changes remarkably similar to those induced in vivo, in the developing neural tube, by RA exposure. This strict correspondence indicates that the neural rosette protocol described is capable of detecting specific teratogenic mechanisms causing perturbations of early neural development and therefore represents a promising alternative test for human prenatal developmental toxicity.
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The evaluation of chemical-induced teratogenicity requires extensive testing to provide all the information needed to ensure the safe use of chemical compounds. At present, in vivo testing for embryotoxicity regulated by Organization for Economic Cooperation and Development (OECD) guideline 414 ''prenatal developmental toxicity'' together with reproductive toxicity, regulated by OECD guidelines 415 and 416, require most of the experimental animals utilized by the chemical industry. For this reason and also because the incoming Registration, Evaluation, Authorisation and Restriction of Chemical Substances EC1907/2006 (REACH) regulation imposes a reduction of the number of animals used for detecting chemical toxicity, the development of alternative testing strategies based on the ''3R'' principle (reduction, refinement, and replacement) has become an urgent challenge for the future of chemical screening. In this context, a large-scale European Union project has been funded (Embryonic Stem cell-based Novel Alternative Testing Strategies, http://www.esnats.eu), with the aim of developing a novel toxicity test platform based on human embryonic stem cells (hESC) covering different aspects of prenatal developmental toxicity. Within this project, we have developed a neural teratogenicity test that aims at detecting adverse chemical effects on early neural differentiation of hESCs.
Recently, we and others have demonstrated (Colleoni et al., 2010; Lee et al., 2007) that hESC are able to differentiate into early neuroectodermal cells in the form of neural rosettes. These peculiar structures represent an in vitro primitive neural stem cell state with all the properties of neural plate cells and recapitulate the early neurulation events that bring the formation and closure of the neural tube and to the emergence of the neural crest (Elkabetz et al., 2008; Lazzari et al., 2006; Pankratz et al., 2007) . We have also demonstrated that neural rosettes derived from HUES1 and HUES3 hESC lines (Cowan et al., 2004 ) possess a highly specific regionalized identity and have a default anteriordorsal pattern, which can be reverted by exposure to inductive ventralizing signals such as sonic hedgehog (SHH) and FGF8. For this high level of plasticity, the rosette in vitro model can be particularly suitable for the development of toxicity tests that target different regions of the developing neural tube.
In vivo neural tube formation and closure is a critical step of embryonic development, and neural tube defects (NTDs) are one of the most common birth defects, affecting on average 0.5-2 newborns per 1000 births (Greene et al., 2009) . Among the possible genetic and environmental causes of NTDs, there is clear evidence that some pharmacological treatments, including therapies with cumarin derivatives (Raghav and Reutens, 2007) , valproic acid (Jergil et al., 2009; Nau et al., 1991) , retinoic acid (RA) (Coberly et al., 1996) , and exposure to toxic substances such as solvents or alcohol (Bowen and Hannigan, 2006) during pregnancy can result in NTDs or in altered neural development syndromes. A clear example is given by the case of retinoids exposure during early gestation: RA has a physiologic function in early neural development and acts as a morphogen in the process of anteroposterior axis specification and early dorsoventral patterning of the spinal cord (Duester, 2009) . For this reason, both deficiency and excess of RA induce developmental related defects. In particular, several studies have reported that hypervitaminosis A causes NTDs (Cai et al., 2007; Luijten et al., 2010) and anomalies involving the tissues derived from cranial neural crest (Mulder et al., 2000) , principally due to a repatterning of the anteroposterior axis of the embryo (Avantaggiato et al., 1996) . Moreover, RA exposure inhibits the movement of neural crest cells and disrupts their migratory pattern (Williams et al., 2004) . Transcriptomic analysis of murine neural crest explants (Williams et al., 2004) and whole rat embryos (Luijten et al., 2010) treated with RA has confirmed that the expression of many genes involved in developmental signaling pathways can be altered by exposure to RA.
Therefore, the aim of this study was to investigate whether hESCs derived neural rosettes, as in vitro model of early neurulation events, could respond to RA exposure with the same perturbations of signaling pathways observed under in vivo conditions, representing a potential in vitro toxicity test for chemical-induced neural teratogenicity.
MATERIALS AND METHODS
hESC culture and neural rosettes generation. Human ESCs (HUES-1 cell line) (Cowan et al., 2004) were cultured on a feeder layer of mouse embryonic fibroblasts (MEFs) inactivated by mitomycin C (Sigma-Aldrich, Milan, Italy, www.sigma-aldrich.com) treatment. Cells were cultured in Knockout-Dulbecco's modified Eagle's medium KO-DMEM (Gibco; Invitrogen, Milan, Italy, www.invitrogen.com) supplemented with 10% serum replacement (Gibco), 4.3 mg/ml bovine serum albumin (Sigma-Aldrich), 2mM glutamine (L-alanyl-l-glutamine, Sigma-Aldrich), 1% nonessential amino acids (Gibco), 0.055mM beta-mercaptoethanol (Gibco), 50 units/ml penicillin and 50 lg/ml streptomycin, and 10 ng/ml bFGF (Fibroblast growth factor, basic PeproTech). Medium was changed daily and cells were passaged with 0.05% trypsin/EDTA on average every 3-4 days.
For the derivation of neural rosettes, growing hESCs were incubated with collagenase (1 mg/ml collagenase type IV, Gibco) at 37°C for 1 h and then the cell monolayer was gently pipetted to detach hESCs colonies from the feeder. The colonies were recovered and cultured in suspension in the same hESCs medium specified above but without the growth factor bFGF in 25 cm 2 flasks (Corning, NY, www.corning.com) to induce the formation of embryoid bodies (EBs). After 4 days, the EBs were singularly plated in matrigel-coated (1:100 dilution; Matrigel, BD, Milan, Italy, www.bd.com) 96-well plates (Nunc, Roskilde, Denmark, www.nuncbrand.com) and cultured in DMEM-F12 medium (DMEM:F12 1:1, Gibco; Invitrogen) supplemented with 0.6% glucose, 3mM sodium bicarbonate, 2mM glutamine, 5mM hepes, 25 lg/ml insulin, 60lM putrescine, 20nM progesterone, 100 lg/ml transferrin, 30nM sodium selenite, 2 lg/ml heparin, and 20 ng/ml bFGF (Colleoni et al., 2010) . Plated EBs were cultured in these conditions for 8 days during which time neural rosettes formation was observed.
Experimental testing strategy design. The design of our testing strategy is illustrated in Figure 1 . RA (Sigma-Aldrich, CAS No. 302-79-4) was dissolved in dimethyl sulfoxide (DMSO) at the maximum solubility of 200mM. Maximum concentration of solvent was determined in preliminary experiments (data not shown) and was fixed at 1 ll/ml (0.1%). For the toxicity test, day 4 EBs were plated singularly in 96-well plates in neural inductive medium in presence of 20 ng/ml of bFGF as indicated above and were allowed to adhere for 24 h. The exposure to RA started 24 h after plating and ended at day 8 after plating. Medium was changed every third day and concentration tested ranged from 2lM to 2nM. In each plate, untreated control and solvent-only treated samples were included. In each test plate, 8-16 wells were destined to each concentration. At the end of the test, the following endpoints were evaluated: number of the plated EBs that originated neural rosettes, neural rosettes morphology, cytotoxicity, and specific neural gene expression markers. The samples were snap-frozen for real-time PCR, stored in RNAprotect Cell Reagent (Qiagen, Milan, Italy) for the microarray analysis or fixed in Paraformaldehyde (4% in PBS) for immunocytochemistry.
Cytotoxicity detection by alamarBlue assay. The cytotoxicity was measured with a test based on reduction of alamarBlue reagent and was performed at the end of the exposure to RA at day 8 after EBs plating. Ten microliters of alamarBlue (alamarBlue, Molecular Probe; Invitrogen, Milan, Italy) were added directly to each well of the 96-well plates containing 100 ll of culture medium. Plates were incubated at 37°C at 5% of CO 2 for 24 h and then the absorbance was measured at 570 nm, using 600 nm as a reference wavelength using a Tecan Sunrise microplate reader (Tecan Trading AG, Switzerland). IC 50 values were calculated using the Prism 5 software.
Microarray gene expression studies. Total RNA was extracted from hESCs treated with three concentrations of RA, exposed only to the solvent and untreated (control). The RNA was extracted using TRIzolchloroform and purified with RNeasy mini columns as recommended by the manufacturer's instructions (Qiagen, Hilden, Germany). All reagents and instrumentation pertaining to oligonucleotide microarrays were procured from Affymetrix (Affymetrix, Santa Clara, CA, http://www.affymetrix.com). Total RNA (100 ng) was used for amplification and in vitro transcription using the GeneChip 3# IVT Express Kit as per the manufacturer's instructions (Affymetrix). The amplified RNA was purified with magnetic beads and 15 lg Biotin-aRNA was fragmented with fragmentation reagent. Fragmented aRNA (12.5lg) was hybridized to Affymetrix Human Genome U133 plus 2.0 arrays along with hybridization cocktail solution and then placed in GeneChip Hybridization FIG. 1. Representative scheme for neural teratogenicity test. hESCs are differentiated into neural rosettes through an EB stage and exposed to the toxic substance during the phase of neural rosettes induction. At the end of the differentiation process, 8 days after the initiation of chemical exposure, the efficiency of neural rosettes generation and the pattern of gene expression are evaluated in exposed versus not exposed cells.
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Oven-645 (Affymetrix) rotating at 60 rpm at 45°C for 16 h. After incubation, arrays were washed on GeneChip Fluidics Station-450 (Affymetrix) and stained with Affymetrix HWS kit as per manufacturer's protocols. The chips were scanned with Affymetrix GeneChip Scanner-3000-7G, and the quality control matrices were confirmed with Affymetrix GCOS software following the manufacturer's guidelines.
Identification of differentially expressed genes. Background correction, summarization, and normalization were done with Robust Multi-array Analysis. The raw data set was normalized with Quantile normalization (Bolstad et al., 2003) method executable with R (Affy)-package (Gautier et al., 2004 ) carried out at probe feature level. Probe sets that were detected to be present were selected and absent were eliminated. MAS5 Expression Summary (Pepper et al., 2007) was used to detect present calls. Only 34,320 probe sets of 54,613 received present calls as defined by the detection p-value of 0.05. The differentially expressed genes were described by a linear model implementing R-LIMMA packages (Linear Models for microarray data, Smyth, 2004) . Data sets of differentially regulated genes based on cutoff values of 5% error rate (p < 0.05, determined by both F-statistics and Moderated t-statistics with Benjamini and Hochberg Multiple Testing Correction) were filtered out fixing control untreated (CTR) sample as common reference and treated samples as experimental samples of both vehicle DMSO treated (1 ll/ml) and RA treated (2, 200, and 2lM). Beside the above-mentioned conditions, fold change value with the threshold value ! (plus minus) 2.0 were used to filter the significantly expressed transcripts. K-mean cluster analysis was performed after transcriptwise normalization of signal values to a mean of 0 and SD of 1 using Euclidean distance measurement and k ¼ 9, using cluster 3.0 tool from Eisen lab (Eisen et al., 1998) Principal component (PC) analysis was performed using the Stats package in R with procomp [6] function. The ''x'' attribute of the procomp object was used to generate two dimensional scatter plots. The first PC axis accounted for 32.6% of the variance in the data set of variable transcripts, and the second accounted for 12.1% (Mardia, 1979) .
Clustering analysis of the differential expressed genes and functional gene ontology classification. We selected only genes whose expression was altered by at least twofold in response to treatment, verified by statistical analysis at a 0.05% significance level (FDR controlled p < 0.05). Transcripts of interest were classified into several groups of known or putative cellular locations and molecular, biological functions using the DAVID database (Database for Annotation, Visualization and Integrated Discovery, http:// david.abcc.ncifcrf.gov/ Huang da et al., 2009) . To derive the biological impact, genes with significant differential expression were annotated based on EASE score enrichment p value (p < 0.01) and clustering stringency at medium level, as per the DAVID tool.
Real-time PCR. The RNeasy mini kit (Qiagen, www.qiagen.com) was employed for RNA isolation using manufacturer's instructions. RNA was reverse transcribed using the iScript complementary DNA (cDNA) synthesis kit (Bio-Rad, Milan, Italy). Real-time PCR reactions were performed in triplicate using iQ SYBR Green Supermix and a MyiQ Real-Time PCR Detection System. Data were analyzed with the iQ Optical System Software (Bio-Rad) with the DDct method. B-Actin was used as housekeeping reference gene, and all the genes were normalized on the untreated control except for FoxA2 and HOXA1 for which the expression was absent in control samples. cDNA was amplified using the specific set of primers listed in Table 1 .
RESULTS

Effect of the Exposure to RA on Rosettes Generation and Morphology
The effects of RA are illustrated in Figure 2 . At the highest concentration tested (2lM), the cells showed reduction of growth and signs of cytotoxicity while, at the same time, rosettes formation was not observed ( Fig. 2A) . At the concentration of 200 and 20nM, RA cell proliferation was clearly stimulated, and rosettes morphology was heavily affected with increased thickness as shown in Figures 2B and  2C . No obvious morphological differences were noted between 2nM exposed cells and untreated control (Figs. 2D and 2E ).
Cytotoxicity
The cytotoxicity was measured by alamarBlue reduction normalized to untreated control samples. The data analyzed by Prism 5 software did not generate a classical sigmoidal cytotoxicity curve because in this system, exposure to RA at relatively low concentrations (10 À9 to 10 À7 M) stimulated the metabolism of the cells until the cytotoxic concentration was reached (Fig. 3) .
Transcriptome Analysis
In order to identify differences in the transcriptomes of control untreated, vehicle (DMSO)-treated and RA-treated hESC, RNA at day 8 of the differentiation protocol was analyzed using Affymetrix HG-U133 Plus 2.0 arrays. After RMA normalization of the 54,613 probe sets excluding internal controls and removing non-or low-expressed transcripts, the remaining 34,320 transcripts were investigated by principal component analysis (PCA) of the five different transcriptomes. Monitoring of the differences in the full transcriptomes is essential for the identification of key biological processes and pathways induced by RA. Therefore, the PCA of the transcriptomes was done to classify the variance in the data set (Fig. 4A) .
The distance between the spheres representing the samples reflects the degree of similarity or difference between the samples. The first two PCs account for 44.7% of the total variance in the data set. PC1 (representing 32.6% variance) shows a clear separation of the untreated and DMSO-treated cells with the RA-treated cells becoming progressively larger with the increasing concentration of the RA (2nM, 200nM, and 2lM) indicating a high degree of similarity of the transcriptomes of the untreated and DMSO-treated hESCs and a clear differences of the transcriptomes of the RA-treated hESCs in a concentration-dependent manner. In PC2, only 12.1% of the total variance could be observed.
K-mean clustering of the differentially expressed probe sets 2550 obtained from ANOVA calculation, resulted in nine different expression profiles (clusters) as shown by the heatmap (Fig. 4B) . The list of abbreviated gene name in the different clusters is included in Supplementary table 1. Clusters 1 and 2 contain genes that are highly expressed in RA-treated cells in a concentration-dependent manner. Among these upregulated genes found in these clusters, a set of genes in cluster 2 has a very low expression level compared with cluster 1. Gene ontology (GO) and KEEG pathway analysis of cluster 1 resulted in identification of several GOTERM_BP_5 genes (Supplementary table 2, in red) belonging to the process of neurogenesis. In cluster 2, several biological processes have been identified associated with the development of mesodermderived organs such as vasculature, bone, and heart (Supplementary table 2, in green) but also genes that are associated with neurogenesis (Supplementary table 2, in red). Interestingly, we also identified biological processes associated with apoptosis (Supplementary table 2, in bold). In cluster 3, genes have been identified that are downregulated in 2lM-treated RA hESCs. Most of the genes belong to GO associated with the proliferation capacity of the cells, suggesting that 2lM RA might be toxic to the cells via inhibition of cell proliferation (Supplementary table 2, in red). As demonstrated in Figure 2A Supplementary table 2 , cluster 8 and 9, in red), such as neurons and brain, as well as GOs associated with development of mesoderm derived organs such as skeletal muscles, heart, and kidney development (Supplementary table 2, in green) . In synthesis RA seems to influence differentiation processes involving ectoderm and mesoderm-derived cells and organs. Quantitative real-time (qRT-PCR) was applied to validate the array data. Specific genes relevant for early neural development were chosen for the validation. Untreated control rosettes were confirmed to be anterior-dorsal patterned by the expression of anterior marker Otx2, Pax6, and dorsal marker Pax7 (data not shown). Exposure to RA radically changed the pattern of the rosettes in a dose-dependent manner for almost all the genes examined. Homeobox genes, commonly upregulated at all concentrations of RA in the microarray study, were examined in the validation study for their highly specific spatiotemporal induction in the developing nervous system. In particular, HoxA1 and HoxA3 were in the top 10 upregulated genes in the 2-200nM samples. qRT-PCR was performed for HoxA1, HoxA3, HoxB1, and HoxB4, and all these genes appeared strongly induced in the treated samples in a dose-dependent manner, while they were completely absent or expressed at very low level in the untreated control (Figs. 5A-D) . Their expression level was statistically different (Student's t-test p < 0.05) from the untreated control for all the concentrations ranging from 20nM to 2lM. Forkhead-box genes FOXC1 and FOXA2 were also chosen for their critical role in the early development and the microarray analysis results were confirmed for both genes. FOXC1 was the most upregulated gene in the 2lM group, whereas FOXA2 was specifically expressed in the 2lM samples (Figs. 5E and 5F ). Anterior marker Otx2 and dorsal marker Pax7 were chosen among the downregulated genes and their downregulation was confirmed in a dose-dependent manner (Figs. 5G and 5H ).
DISCUSSION
The primary objective of this study was to assess if a hESCbased in vitro model of neurulation could be developed into a reliable alternative method for the detection of early neural teratogenicity. To address this question, we have applied a previously established protocol of hESCs neural differentiation (Colleoni et al., 2010) , which mimics the formation of the cranial neural tube giving rise to neural rosettes expressing Otx2, Pax6, and Pax7 and surrounded by p75 positive neural crest precursors cells. We have exposed the cells to different concentrations of RA, and we have performed a comparative analysis of the effects observed in vitro versus the welldescribed in vivo effects of this teratogenic compound. We have compared morphological and molecular changes induced by RA exposure with particular attention to the expression of genes critical for early neural development.
The consequences of human in utero exposure to RA include malformations to craniofacial, cardiac, thymic, and central nervous system structures, which have been correlated with a perturbation of the cranial neural crest formation process (Lammer et al., 1985) . In vivo studies on animal models have confirmed and integrated these observations, demonstrating that RA can act on primary or secondary neurulation in relation to the developmental period of exposure, causing different effects on cranial neural crest-derived structures (Mulder et al., 2000) or on lumbosacral regions of the neural tube (Cai et al., 2007; Griffith and Zile, 2000) , respectively. Since the rosette model described is anterior-dorsal patterned, we expected, as a consequence of RA exposure, a strong perturbation of the differentiation pattern. In fact, transcriptomic data analysis indicated that RA-exposed cells displayed a significantly different pattern of gene expression compared with untreated cells, as shown in the 2D graph of PCA. We observed that, among the genes differentially expressed, the most upregulated transcripts were included in the GO categories related to embryonic organ morphogenesis and development, anterior/ posterior pattern formation, cranial nerve morphogenesis, pattern specification process, neuron differentiation and development, neural tube formation and closure, embryonic morphogenesis, regionalization, and sensory organ development. These genes include those of the homeobox family, such as HoxA1, HoxA2, HoxA3, HoxB2, HoxB3, and of the forkhead transcription factor family, such as FoxC1. In these classes were also included genes of the paired box family such as Pax6 and Pax3, Otx2, and genes related to the frizzled family, indicating an involvement of the Wnt and SHH pathways. In A NEURAL TERATOGENICITY TEST BASED ON hESCs 375 parallel, the Reelin and Wnt signaling pathways, playing a key role during neuron migration (Huang, 2009) and development (Hur and Zhou, 2010) , were found to be suppressed in RAtreated cells. Indeed, the most upregulated transcripts in the 2lM group were those of the categories involved in transcription factor and regulator activity, in sequence-specific DNA binding, and in cardiac and muscle tissue development (FoxA2, FoxC1, HoxD4 and FoxP1). Microarray analysis also showed that the results of this study are in agreement with previously generated transcriptomics data from neural crest murine explants (Williams et al., 2004) and whole rat embryos (Luijten et al., 2010) exposed to RA, indicating a remarkable correspondence between the different biological systems.
qRT-PCR validation of the microarray confirmed a doseresponse activation of the homeobox family genes, in particular of HoxA1, HoxA3, HoxB1, and HoxB4. Notably, in vivo these 3# Hox genes are directly regulated by RA through their conserved RAREs sequences (RA responsive elements) (Duester, 2007) and are the earliest genes activated by RA in a concentrationdependent manner (Marshall et al., 1996) . Moreover, in vivo studies have shown that RA alters the Hox pattern of expression, inducing a shift to the anterior part of the neural tube where they are normally not present (Marshall et al., 1992) . The ectopic expression of these genes is accompanied by a strong downregulation of anterior markers, in particular of Otx2, whose repression could be co-responsible for the RA-induced malformations (Acampora et al., 1995; Ang et al., 1996; Avantaggiato et al., 1996) . In our in vitro system, we detected the same dosedependent downregulation of Otx2. Another important in vivo function of Otx2 is the maintenance of the anteroposterior axis and, to some extent, the antagonization of posteriorizing genes. In a model of Otx2 mutant mice, a gradual downregulation of Otx2 causes a dorsal extension of floor plate genes expression such as SHH and FoxA2, and a specific threshold of Otx proteins seems to be necessary to repress FoxA2 (Puelles et al., 2003) . The same correlation between Otx2 expression level and FoxA2 activation was observed in this study, where FoxA2 was upregulated only at the highest concentration of RA, at which point the expression of Otx2 was at the lowest level. As a consequence of this profound pattern change, also the typical dorsal marker Pax7 was downregulated, indicating a perturbation of the process of cranial neural crest formation (Mansouri et al., 1996) .
A further validation of the microarray data was performed by qRT-PCR demonstrating an elevated expression of FoxC1. In vivo FoxC1 is expressed early in development and defects observed in mutant models, including ocular, cardiac, and craniofacial abnormalities, are similar to those induced by exposure to RA (Cha et al., 2007) . Notably, all FoxC1 mutations causing either upregulation or downregulation of this gene lead to developmental abnormalities, and for that reason a proper level of FoxC1 expression is crucial for normal development (Nishimura et al., 2001) .
Taken together, all these findings indicate that RA deeply modifies the morphology and the molecular differentiation pattern of hESCs-derived neural rosettes in a dose-dependent manner, inducing a shift from anterior-dorsal to posterior identity in vitro as clearly demonstrated in vivo (Avantaggiato et al., 1996; Marshall et al., 1992) . This strict correspondence provides a solid platform for further validation of this method as a reliable in vitro test for prenatal developmental neural teratogenicity. Moreover, since we have previously demonstrated that the default anterior-dorsal neural rosettes identity can be ventralized or posteriorized, the high plasticity of this model makes it particularly suitable for chemical screening to detect subtle perturbations of early neural development. Exposure trials with other teratogenic reference substances are ongoing to extend the data set and fine-tune the reliability of the test.
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